ABX203 (HeberNasvac) Granted Cuban Marketing Authorization to Treat Chronic Hepatitis B
ABX203 (HeberNasvac) Granted Cuban Marketing Authorization to Treat Chronic Hepatitis B
December 8, 2015
Download 111.7 KB
Paris, France - December 8th 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral and vaccine therapies for diseases like HIV/AIDS and chronic Hepatitis B (CHB) and the Center for genetic Engineering and Biotechnology (CIGB), a global leader in bio today announced that CECMED, the Cuban regulatory authorities, granted the CIGB their first marketing authorization application for ABX203, a first-in-class therapeutic vaccine for treatment of CHB, under the trade name HeberNasvac.